Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

What Is the Evidence That Tumors Are Angiogenesis Dependent?

Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486

Thomas, Springfield, Illinois

MAGOUN, H. N. (1965) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196504000-00011 · Cited by 2,932

Clinical Applications of Research on Angiogenesis

Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,251

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,891

Angiostatin induces and sustains dormancy of human primary tumors in mice

O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents

Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 443

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.

Singh, R. K., Gutman, M., BUCANA, C. D., Sanchez, R. R., Llansa, N., & Fidler, I. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4562 · Cited by 437

Tumor angiogenesis and tissue factor

Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0296-167 · Cited by 290

Current results of the screening program at the division of cancer treatment, national cancer institute

GOLDIN, A. S., Venditti, J. M., Macdonald, J. S., Muggia, F. M., Henney, J. E., & DeVita, V. T. (1981) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(81)90027-x · Cited by 209

Antisense HIF-1α prevents acquired tumor resistance to angiostatin gene therapy

Sun, X., Vale, M., Jiang, X. L., Gupta, R., & Krissansen, G. W. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.7 · Cited by 23

Oligosaccharides as anti-angiogenic agents

Cole, C. L., & Jayson, G. C. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.3.351 · Cited by 23

A Pilot Trial of Suramin in Metastatic Breast Cancer to Assess Antiangiogenic Activity in Individual Patients

Gradishar, W. J., Soff, G. A., Liu, J., Cisneros, A., French, S. L., RADEMAKER, A. W., Benson, A. B., & Bouck, N. (2000) · Oncology · doi:10.1159/000012120 · Cited by 23

Improved biological activity of a mutant endostatin containing a single amino-acid substitution

Yokoyama, Y., & Ramakrishnan, S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601745 · Cited by 23

Rapidly acting antitumoral antiangiogenic therapies

d’Onofrio, A. (2007) · Physical Review E · doi:10.1103/physreve.76.031920 · Cited by 23

Optimal control for combination therapy in cancer

Ledzewicz, U., Schättler, H., & d’Onofrio, A. (2008) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc.2008.4738880 · Cited by 23

Cellular Actions and Signaling by Endostatin

Ramchandran, R., Karumanchi, S. A., Hanai, J., Alper, S. L., & Sukhatme, V. P. (2002) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.v12.i3.20 · Cited by 23

Schedule-Dependent Pulsed Paclitaxel Radiosensitization for Thoracic Malignancy

Chen, Y., Pandya, K. J., Keng, P., Feins, R. H., Raubertas, R. F., Smudzin, T., Rosenblatt, J. D., & Okunieff, P. (2001) · American Journal of Clinical Oncology · doi:10.1097/00000421-200110000-00004 · Cited by 23

Angiogenesis in head and neck squamous cell carcinoma

Homer, J. J., Greenman, J., & Stafford, N. (2000) · Clinical Otolaryngology · doi:10.1046/j.1365-2273.2000.00356.x · Cited by 23

Characterization of Rat Aortic Fragment within Collagen Gel as an Angiogenesis Model; Capillary Morphology may Reflect the Action Mechanisms of Angiogenesis Inhibitors.

Hata-Sugi, N., Kageyama‐Kawase, R., & Wakabayashi, T. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.446 · Cited by 23

Anti-angiogenic Chemotherapy in Central Nervous System Tumors

Kieran, M. W. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_19 · Cited by 23

Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of TSA in cancer therapy

Ailenberg, M., & Silverman, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00150-5 · Cited by 23

Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice

Liu, P., Wang, Y., Li, Y.-H., Yang, C., Zhou, Y., Li, B., Lu, S., Yang, R., Cai, Y.-L., Tobelem, G., et al. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00346-6 · Cited by 23

Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma

Choi, L. M. R., Kim, N. W., Zuo, J. J., Gerbing, R. B., Stram, D. O., Lukens, J. N., Matthay, K. K., Seeger, R. C., & Reynolds, C. P. (2000) · Medical and Pediatric Oncology · doi:10.1002/1096-911x(20001201)35:6 · Cited by 30

Inhibition of vascular endothelial growth factor in the treatment of solid tumors

Margolin, K. A. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0044-9 · Cited by 23

Disruption of integrin-dependent adhesion and survival of endothelial cells by recombinant adenovirus expressing isolated β integrin cytoplasmic domains

Oguey, D., George, P., & Rüegg, C. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301236 · Cited by 23

Tumour regression after endostatin therapy

Black, W. R., & Agner, R. C. (1998) · Nature · doi:10.1038/35064 · Cited by 23

Prostatic angiogenic responses in late life: Antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model

Montico, F., Kido, L. A., Hetzl, A. C., & Cagnon, V. H. A. (2014) · The Prostate · doi:10.1002/pros.22934 · Cited by 22

Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells

Mu, X., Sang, Y., Fang, C., Shao, B., Yang, L., Yao, K., Zhao, X., Gou, J., Wei, Y., Yi, T., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3175 · Cited by 22

A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer

Shin, S. J., Jeung, H., Ahn, J. B., Rha, S. Y., Roh, J. K., Park, K. S., Kim, D. H., Kim, C., & Chung, H. C. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9287-8 · Cited by 22

Butyrate-induced phosphatase regulates VEGF and angiogenesis via Sp1

Kumar, S. P., Thippeswamy, G. B., Sheela, M. L., Prabhakar, B. T., & Salimath, B. P. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.07.004 · Cited by 22

(1,2,3-Triazol-4-yl)benzenamines: Synthesis and activity against VEGF receptors 1 and 2

Kiselyov, A. S., Semenova, M. N., & Semenov, V. V. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.01.046 · Cited by 22

High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine

Boodhwani, M., Mieno, S., Voisine, P., Feng, J., Sodha, N. R., Li, J., & Sellke, F. W. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.05.060 · Cited by 22

The Clinical Application of Ozonetherapy

Bocci, V. A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9234-2_9 · Cited by 24

Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers

Amirghasemi, F., Adjei‐Sowah, E., Pockaj, B. A., & Nikkhah, M. (2021) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02704-9 · Cited by 25

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

Liu, C.-T., Hsieh, M., Su, Y., Hung, C.-M., Pei, S., Liao, C., Tsai, Y.-F., Liao, H., Liu, W.-C., Chiu, C., et al. (2021) · Journal of Cancer · doi:10.7150/jca.60682 · Cited by 22

Angiogenèse tumorale: physiopathologie, valeur pronostique et perspectives thérapeutiques

André, T., Chastre, E., Kotelevets, L., Vaillant, J., Louvet, C., Balosso, J., Gall, E. L., Prevot, S., & Gespach, C. P. (1998) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(99)80063-0 · Cited by 22

Improved therapeutic efficacy against murine carcinoma by combining honokiol with gene therapy of PNAS‐4, a novel pro‐apoptotic gene

Yuan, Z., Liu, H., Yan, F., Wang, Y., Gou, L., Nie, C., Ding, Z., Lai, S., Zhao, Y., Zhao, X., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01242.x · Cited by 22

Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression

Ohnuma, Y., Toda, M., Fujita, M., Hosono, K., Suzuki, T., Ogawa, Y., Amano, H., Kitasato, H., Hayakawa, K., & Majima, M. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.11.005 · Cited by 22

Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials

Mross, K. B. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0150 · Cited by 22

Chronic Administration of Single-Agent Paclitaxel in Gynecologic Malignancies

Rohl, J., Kushner, D. M., & Markman, M. M. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6142 · Cited by 22

Mouse Dendritic-Endothelial Cell Hybrids and 4-1BB Costimulation Elicit Antitumor Effects Mediated by Broad Antiangiogenic Immunity

Ko, E. C., Luo, W., Peng, L., Wang, X., & Ferrone, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1744 · Cited by 22

Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin

Ryan, D. P., Penson, R. T., Ahmed, S., Chabner, B. A., & Lynch, T. J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_2-58 · Cited by 22

Angiogenesis, a target for tumor therapy

Griffioen, A. W., Barendsz-Janson, A. F., Mayo, K. H., & Hillen, H. F. P. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90106-8 · Cited by 22

Quantitating Therapeutic Disruption of Tumor Blood Flow with Intravital Video Microscopy

Iga, A. M., Sarkar, S., Sales, K. M., Winslet, M. C., & Seifalian, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1743 · Cited by 22

Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor RNasin

Estrada, R. B., Malet‐Engra, G., Revert, F., Dası́, F., Crespo, A., Sanmartín, O., Guillén, C., & Aliño, S. F. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700302 · Cited by 22

Anti-angiogenic properties of Chemopreventive Drugs: Fenretinide as a Prototype.

Sogno, I., Venè, R., Sapienza, C., Ferrari, N., Tosetti, F., & Albini, A. (2008) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-69297-3_8 · Cited by 22

Antiangiogenic therapy for primary and metastatic brain tumors

Purow, B. W., & Fine, H. A. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.05.003 · Cited by 22

The Anti-Angiogenic Activity of Human Endostatin Inhibits Bladder Cancer Growth and Its Mechanism

Du, Z., & Hou, S.-K. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000091879.18156.22 · Cited by 22

ANTIANGIOGENESIS THERAPY

Kieran, M. W., & Billett, A. L. (2001) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70254-9 · Cited by 22

Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft

Fu, X., Li­, ­., Zou, Y., Hong, Y., Fu, Z., Huang, J., Zhang, S., & Zheng, S. S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.008 · Cited by 21

Ardisia crispa root hexane fraction suppressed angiogenesis in human umbilical vein endothelial cells (HUVECs) and in vivo zebrafish embryo model

Jun, L. W., Foong, C. P., & Hamid, R. A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109221 · Cited by 21

Proteoglycans of basement membranes: Crucial controllers of angiogenesis, neurogenesis, and autophagy

Mongiat, M., Pascal, G. J., Poletto, E., Williams, D. M., & Iozzo, R. V. (2024) · Proteoglycan Research · doi:10.1002/pgr2.22 · Cited by 21

High-Level Expression and Secretion of Recombinant Mouse Endostatin by Escherichia coli

Xu, R., Du, P., Fan, J., Zhang, Q., Li, T., & Gan, R.-B. (2002) · Protein Expression and Purification · doi:10.1006/prep.2001.1585 · Cited by 21

Therapeutic efficacy of Bifidobacterium longum‐mediated human granulocyte colony‐stimulating factor and/or endostatin combined with cyclophosphamide in mouse‐transplanted tumors

Zhu, L., Yin, Y., Xing, J., Li, C., Kou, L., Hu, B. R., Wu, Z., Wang, J., & Xu, G. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01275.x · Cited by 21

Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models

Ren, Z., Wang, Y., Jiang, W., Dai, W. H., & Jiang, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107823 · Cited by 21

Inhibitory effect of recombinant human endostatin on the proliferation of hypertrophic scar fibroblasts in a rabbit ear model

Gong, Y., Zhang, X. M., Liu, F., Wang, Z., Deng, X., Yi, J., Li, X., & Huang, X. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.09.034 · Cited by 21

Usefulness of HIF-1 Imaging for Determining Optimal Timing of Combining Bevacizumab and Radiotherapy

Ou, G., Itasaka, S., Zeng, L., Shibuya, K., Yi, J., Harada, H., & Hiraoka, M. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.02.083 · Cited by 21

De novo expression of the cell adhesion molecule E-selectin on gastric cancer endothelium

Mayer, B., Spatz, H., Funke, I., Johnson, J. P., & Schildberg, F. W. (1998) · Langenbeck s Archives of Surgery · doi:10.1007/s004230050096 · Cited by 21

Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis

Schättler, H., Ledzewicz, U., & Cardwell, B. (2011) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2011.8.355 · Cited by 21

Combination therapy with tumor‐lysate pulsed dendritic cells and antiangiogenic drug TNP‐470 for mouse pancreatic cancer

Miyazaki, J., Tsuzuki, Y., Matsuzaki, K., Hokari, R., Okada, Y., Kawaguchi, A., Nagao, S., Itoh, K., & Miura, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21202 · Cited by 21

Progress Report on the Potential of Angiogenesis Inhibitors for Neuro-Oncology

Purow, B. W., & Fine, H. A. (2004) · Cancer Investigation · doi:10.1081/cnv-200027141 · Cited by 21

Luminacins. A Family of Capillary Tube Formation Inhibitors from Streptomyces sp. I. Taxonomy, Fermentation, Isolation, Physico-chemical Properties and Structure Elucidation.

NARUSE, N., Kageyama‐Kawase, R., Funahashi, Y., WAKABAYASHI, T., Watanabe, Y., Sameshima, T., & Dobashi, K. (2000) · The Journal of Antibiotics · doi:10.7164/antibiotics.53.579 · Cited by 21

Bang-bang and singular controls in a mathematical model for combined anti-angiogenic and chemotherapy treatments

Ledzewicz, U., Maurer, H., & Schättler, H. (2009) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc.2009.5400735 · Cited by 21

Effect of human recombinant Endostatin® protein on human angiogenesis

Jung, S. P., Siegrist, B., Hornick, C. A., Wang, Y., Wade, M. R., ANTHONY, C. T., & Woltering, E. A. (2002) · Angiogenesis · doi:10.1023/a:1021540328613 · Cited by 21

Matrix Molecules and Their Ligands

Olsen, B. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00010-0 · Cited by 21

Delayed Vascular Changes after Antiangiogenic Therapy with Antivascular Endothelial Growth Factor Antibodies in Human Glioma Xenografts in Nude Mice

Bernsen, H. J. J. A., Rijken, P. F. J. W., Peters, J. P. W., Bakker, H. H., & van der Kogel, A. J. (1998) · Neurosurgery · doi:10.1097/00006123-199809000-00094 · Cited by 21

New Molecular Strategies to Cure Brain Tumors

Fathallah‐Shaykh, H. M. (1999) · Archives of Neurology · doi:10.1001/archneur.56.4.449 · Cited by 21

Molecular markers for diagnosis, staging, and prognosis of bladder cancer.

Williams, S. G., Buscarini, M., & Stein, J. P. (2001) · PubMed · Cited by 21

Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status

Anakha, J., Dobariya, P., Sharma, S. S., & Pande, A. H. (2023) · Medical Oncology · doi:10.1007/s12032-023-02245-w · Cited by 23

The HUVEC/Matrigel Assay: An In Vivo Assay of Human Angiogenesis Suitable for Drug Validation

Skovseth, D. K., Küchler, A. M., & Haraldsen, G. (2006) · Humana Press eBooks · doi:10.1385/1-59745-165-7:253 · Cited by 20

Vaccination with xenogeneic tumor endothelial proteins isolated in situ inhibits tumor angiogenesis and spontaneous metastasis

Zhang, W., Liu, J., & Tan, X. (2009) · International Journal of Cancer · doi:10.1002/ijc.24362 · Cited by 20

The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth

Ehnman, M., Li, H., Fredriksson, L., Pietras, K., & Eriksson, U. (2008) · Oncogene · doi:10.1038/onc.2008.410 · Cited by 20

Expression of thymidine kinase mediated by a novel non-viral delivery system under the control of vascular endothelial growth factor receptor 2 promoter selectively kills human umbilical vein endothelial cells

Wang, Y., Xu, H.-X., Lu, M., & Tang, Q. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.224 · Cited by 20

Endostatin and anastellin inhibit distinct aspects of the angiogenic process

Neskey, D. M., Ambesi, A., Pumiglia, K. M., & McKeown‐Longo, P. J. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-61 · Cited by 20

Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas

Fenton, B. M., Paoni, S. F., Grimwood, B. G., & Ding, I. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)01430-5 · Cited by 20

Inhibition of angiogenesis at endothelial cell level

Jekunen, A. P., & Kairemo, K. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10247 · Cited by 20

Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model

Hong, S.-Y., Lee, M. H., Kim, K., Chung, H. C., Roh, J. K., Hyung, W. J., Noh, S. H., & Choi, S. H. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i8.1191 · Cited by 20

Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases

Kim, T. H., Kim, E., Yoon, D., Kim, J., Rhim, T. Y., & Kim, S. S. (2002) · Angiogenesis · doi:10.1023/a:1023835102832 · Cited by 20

SYNERGISTIC INHIBITION OF TUMOR GROWTH AND METASTASIS BY COMBINED TREATMENT WITH TNP-470 AND GEMCITABINE IN A HUMAN BLADDER CANCER KOTCC-1 MODEL

Muramaki, M., Miyake, H., Hara, I., Kawabata, G., & Kamidono, S. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000133653.74536.43 · Cited by 20

Immune Response Against 3LL Lewis Lung Carcinoma Potentiates the Therapeutic Efficacy of Endostatin

Li, M., Huang, X., Zhu, Z.-Y., Wong, M. K. K., Watkins, S. C., Zhao, Q., Herberman, R. B., & Gorelik, E. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200111000-00004 · Cited by 20

An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas.

Melero, I., Gabari, I., Corbí, A. L., Relloso, M., Mazzolini, G. D., Schmitz, V., Rodrı́guez-Calvillo, M., Tirapu, I., Camafeita, E., Albar, J. P., et al. (2002) · PubMed · Cited by 20

Oncogenes and Tumor Angiogenesis

Rak, J. W., & Kerbel, R. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-313-2_10 · Cited by 20

Inhibition of B16BL6 tumor progression by coadministration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes

Kim, K. S., Kim, H. S., Park, J. S., Kwon, Y. G., & Park, Y. S. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700716 · Cited by 20

Pretargeted Peptide Imaging and Therapy

Goodwin, D. A., & Meares, C. F. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.145 · Cited by 20

Expression of the Endostatin gene in epithelial ovarian cancer.

Hata, K., Fujiwaki, R., Nakayama, K., & Miyazaki, K. (2001) · PubMed · Cited by 20

Thioredoxin Delays Photoreceptor Degeneration, Oxidative and Inflammation Alterations in Retinitis Pigmentosa

Gimeno-Hernández, R., Cantó, A., Fernández-Carbonell, Á., Olivar, T., Hernández‐Rabaza, V., Almansa, I., & Miranda, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.590572 · Cited by 19

Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways

Kumar, R., Deep, G., Wempe, M. F., Agarwal, R., & Agarwal, C. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009614666141229102254 · Cited by 19

Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth

Liang, P., Zhang, K., Xu, G., 李彦锋, Wang, L., Nie, Z., Ye, J., Wu, G., Ge, C., & Jin, F. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0727-2 · Cited by 19

Anti-Angiogenic and Pro-Apoptotic Effects of Dietary Restriction in Experimental Brain Cancer: Role of Glucose and Ketone Bodies

Seyfried, T. N., & Mukherjee, P. (2005) · Springer eBooks · doi:10.1007/1-4020-3414-8_15 · Cited by 19

Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice

Emoto, M., Ishiguro, M., Iwasaki, H., Kikuchi, M., & Kawarabayashi, T. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00155-5 · Cited by 19

Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin

Ryan, D. P., Penson, R. T., Ahmed, S., Chabner, B. A., & Lynch, T. J. (1999) · The Oncologist · doi:10.1634/theoncologist.4-6-501 · Cited by 19

Angiogenesis Inhibitors as Cancer Therapy

Eckhardt, S. G. (1999) · Hospital Practice · doi:10.3810/hp.1999.01.124 · Cited by 19

Livistona extract inhibits angiogenesis and cancer growth

Sartippour, M. R., Liu, C., Shao, Z., Go, V. L. W., Heber, D., & Nguyen, M. T. N. (2001) · Oncology Reports · doi:10.3892/or.8.6.1355 · Cited by 19

Antitumor Effects Induced by the Combination of TNP-470 as an Angiogenesis Inhibitor and Lentinan as a Biological Response Modifier in a Rabbit Spontaneous Liver Metastasis Model

佐野, 文., Sugiyama, Y., Kunieda, K., Sano, J., & Saji, S. (2002) · Surgery Today · doi:10.1007/s005950200085 · Cited by 19

A NEW COLLOIDAL LIPIDIC SYSTEM FOR GENE THERAPY

Fahr, A., Müller, K., Nahde, T., Müller, R., & Brüsselbach, S. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120004774 · Cited by 19

Generation of Expression Plasmids for Angiostatin, Endostatin and Timp-2 for Cancer Gene Therapy

Indraccolo, S., Minuzzo, S. A., Gola, E., Habeler, W., Carrozzino, F., Noonan, D. M., Albini, A., Santi, L., Amadori, A., & Chieco‐Bianchi, L. (1999) · The International Journal of Biological Markers · doi:10.1177/172460089901400410 · Cited by 19

Anti-angiogenic therapies in cancer clinical trials

Zhang, H., & Harris, A. L. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.10.1629 · Cited by 19

Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy

Blaheta (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000125 · Cited by 18

Dose-reduction antiangiogenic curcumin-low molecular weight heparin nanodrugs for enhanced combinational antitumor therapy

Xiao, Y., Xu, C., Xiong, H., Du, S. M., Zhou, J., Yin, L., & Yao, J. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.04.011 · Cited by 18

Tetrahydrocurcumin-Related Vascular Protection: An Overview of the Findings from Animal Disease Models

Zhang, L., Li, C., Wang, S., Avtanski, D. B., Hadzi‐Petrushev, N., Mitrokhin, V. M., Mladenov, M. I., & Wang, F. (2022) · Molecules · doi:10.3390/molecules27165100 · Cited by 18

Generation and Characterization of Recombinant Vascular Targeting Agents from Hybridoma Cell Lines

Gottstein, C., Wels, W. S., Ober, B. T., & Thorpe, P. E. (2001) · BioTechniques · doi:10.2144/01301dd03 · Cited by 18

Inhibitors of Fatty Acid Synthesis in Prokaryotes and Eukaryotes as Anti-Infective, Anticancer and Anti-Obesity Drugs

Wang, J., Hudson, R., & Sintim, H. O. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.62 · Cited by 19

Anti-vascular therapy: a new approach to cancer treatment

Hayes, A. J. (2000) · Western Journal of Medicine · doi:10.1136/ewjm.172.1.39 · Cited by 18

Process in the mechanisms of endostatin combined with radiotherapy

Zhuang, H., & Yuan, Z. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.008 · Cited by 18

Angiogenesis in ovarian cancer: Molecular pathology and therapeutic strategies

Paley, P. J. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0078-z · Cited by 18

Vandetanib Improves Anti-Tumor Effects of L19mTNFα in Xenograft Models of Esophageal Cancer

Crescenzi, M., Persano, L., Esposito, G., Zulato, E., Borsi, L., Balza, E., Ruol, A., Ancona, E., Indraccolo, S., & Amadori, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1420 · Cited by 18

The history of angiogenesis inhibitors

Ribatti, D. (2007) · Leukemia · doi:10.1038/sj.leu.2404756 · Cited by 15

Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives

Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E. (2024) · Cancers · doi:10.3390/cancers16050890 · Cited by 11

Pathophysiology of ischaemia-reperfusion injury

Carden, D. L., & Granger, D. N. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200002)190:3 · Cited by 5

A flanking attack on cancer

Hanahan, D. (1998) · Nature Medicine · doi:10.1038/nm0198-013 · Cited by 63

Resisting Arrest

(2005) · Science · doi:10.1126/science.310.5751.1091a

Antiangiogenic cancer treatment

Alfred, J. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01435-8

Endostatin: The logic of antiangiogenic therapy

Abdollahi, A., Hlatky, L., & Huber, P. E. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.03.001 · Cited by 119

Anti-angiogenic strategies for cancer therapy (Review)

Benouchan, M., & Colombo, B. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.2.563 · Cited by 29